Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trialBrad H. Rovin, Catarina Almeida, Ulysses Diva et al.|The Lancet|2023Cited by 264
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trialHiddo J.L. Heerspink, Toby Coates, Jai Radhakrishnan et al.|The Lancet|2023Cited by 214
Alport Syndrome in Women and GirlsJudy Savige, Frances Flinter, Deb Colville et al.|Clinical Journal of the American Society of Nephrology|2016Cited by 147